Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC)
| Autor: | Emmanuel Benizri, Marianne Cegarra-Escolano, Mariangela Desantis, Amine Rahili, Jean-Marc Bereder, Jean-Louis Bernard, Daniel Benchimol, Vincent Casanova |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Disease-Free Survival Stomach Neoplasms Cytoreduction Surgical Procedures Humans Medicine Combined Modality Therapy Infusions Parenteral Adverse effect Peritoneal Neoplasms Aged Ovarian Neoplasms business.industry Mortality rate Hyperthermia Induced Middle Aged Vascular surgery Prognosis Pseudomyxoma Peritonei Surgery Cardiothoracic surgery Multivariate Analysis Female Hyperthermic intraperitoneal chemotherapy Colorectal Neoplasms business Abdominal surgery |
| Zdroj: | Langenbeck's Archives of Surgery. 400:37-48 |
| ISSN: | 1435-2451 1435-2443 |
| DOI: | 10.1007/s00423-014-1253-z |
| Popis: | Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are a novel curative treatment option for selected patients with peritoneal carcinomatosis (PC). We aimed to report the mortality rate and the most frequent grade III-IV adverse events and to identify associated prognostic markers. We report oncological outcomes and major prognostic factors influencing overall survival (OS) and disease-free survival.A total of 401 CRS plus HIPEC procedures were performed on 356 patients. Mortality, grade III-IV adverse events, OS, disease-free survival, and prognostic factors were studied.Based on Common Terminology Criteria for Adverse Events (CTCAE of the National Cancer Institute 2006), mortality rate was 1 % and overall rate of morbidity grade III-IV was 12.5 %. In multivariate analysis, only the number of digestive anastomoses (1) significantly correlated with adverse events with an odds ratio of 2.8 (p = 0.032). OS was related to histological type of PC, with a median survival reaching 47.6 months for PC of ovarian cancer origin, 45.8 months for that of colorectal origin, 64.2 months for peritoneal mesothelioma, and 8.1 months for PC of gastric cancer origin. Over half the patients with pseudomyxoma are still alive. Major prognostic factors influencing survival were histological type, World Health Organization performance status (WHO PS) (hazard ratio (HR) = 3.56), operating time (HR = 0.45), previous chemotherapy (HR = 2.04), number of peritonectomies (HR = 2.03), and completeness of cytoreduction score (HR = 3.12). Disease-free survival across all groups was 16.8 months.The low mortality rate and 12.5 % grade III-IV morbidity of CRS and HIPEC are acceptable when weighed against overall oncologic survival. This multimodal treatment appears feasible for selected patients and trained centers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink